Drugs / UCART20x22
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05607420 | Nov 2022 → Aug 2027 expected | B-cell non-Hodgkin lymphoma | Cellectis S.A. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCART20x22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05607420 ↗ |
| Modality | Cell therapy | “Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors” NCT05607420 ↗ |
| Route | Intravenous | “UCART20x22 administered intravenously” NCT05607420 ↗ |